GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Cyclically Adjusted Book per Share

Summit Therapeutics (Summit Therapeutics) Cyclically Adjusted Book per Share : $1.59 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Summit Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.111. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.59 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Summit Therapeutics's average Cyclically Adjusted Book Growth Rate was -4.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Summit Therapeutics was 0.90% per year. The lowest was -11.80% per year. And the median was -5.45% per year.

As of today (2024-04-30), Summit Therapeutics's current stock price is $3.94. Summit Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.59. Summit Therapeutics's Cyclically Adjusted PB Ratio of today is 2.48.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Summit Therapeutics was 5.79. The lowest was 0.47. And the median was 1.19.


Summit Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Summit Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Cyclically Adjusted Book per Share Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.43 1.55 1.53 1.67 1.59

Summit Therapeutics Quarterly Data
Jan19 Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.70 1.68 1.64 1.59

Competitive Comparison of Summit Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Summit Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Cyclically Adjusted PB Ratio falls into.



Summit Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Summit Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.111/129.4194*129.4194
=0.111

Current CPI (Dec. 2023) = 129.4194.

Summit Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201401 1.627 98.692 2.134
201404 0.000 100.023 0.000
201407 4.118 100.520 5.302
201410 3.436 100.176 4.439
201501 2.375 98.604 3.117
201504 4.284 99.824 5.554
201507 3.846 100.691 4.943
201510 3.261 100.346 4.206
201601 1.868 99.957 2.419
201604 1.941 100.947 2.488
201607 1.136 101.524 1.448
201610 0.108 101.988 0.137
201701 -0.353 102.456 -0.446
201704 -0.833 103.167 -1.045
201707 0.371 103.278 0.465
201710 1.513 104.070 1.882
201801 -0.303 104.578 -0.375
201804 0.485 105.708 0.594
201807 2.643 106.324 3.217
201810 2.165 106.695 2.626
201901 1.739 106.200 2.119
201904 1.557 107.818 1.869
201907 1.277 108.250 1.527
201910 1.080 108.577 1.287
202003 1.003 108.902 1.192
202006 0.000 108.767 0.000
202009 0.548 109.815 0.646
202012 0.962 109.897 1.133
202103 0.777 111.754 0.900
202106 1.227 114.631 1.385
202109 1.048 115.734 1.172
202112 0.849 117.630 0.934
202203 0.656 121.301 0.700
202206 0.523 125.017 0.541
202209 0.662 125.227 0.684
202212 0.600 125.222 0.620
202303 0.191 127.348 0.194
202306 0.171 128.729 0.172
202309 0.142 129.860 0.142
202312 0.111 129.419 0.111

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Summit Therapeutics  (NAS:SMMT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Summit Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.94/1.59
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Summit Therapeutics was 5.79. The lowest was 0.47. And the median was 1.19.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Summit Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (Summit Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Summit Therapeutics (Summit Therapeutics) Headlines

From GuruFocus

Summit Therapeutics' Rights Offering Nearing Expiration Date

By Business Wire Business Wire 02-23-2023